Enrollment Advancing in Phase 2 Trial of NP-120 for Chronic Cough in IPF

Enrollment Advancing in Phase 2 Trial of NP-120 for Chronic Cough in IPF

294266

Enrollment Advancing in Phase 2 Trial of NP-120 for Chronic Cough in IPF

Algernon Pharmaceuticals has announced that its Phase 2 trial of oral NP-120 (ifenprodil) in treating chronic cough associated with idiopathic pulmonary fibrosis (IPF) has reached 50% of its enrollment target. The proof-of-concept and open-label study (NCT04318704), currently underway at four sites in Australia and two in New Zealand, aims to enroll 20 patients and is actively recruiting. Additional information on locations and study contacts may be found here. A chronic or persistent cough, or a cough lasting at…

You must be logged in to read/download the full post.